TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07072728: A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With

Sponsor: Psyence Australia Pty Ltd · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 87 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,883,800

Rescue Site Savings

+$4,527,600

Unlock Full NCT07072728 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07072728 Rescue Dossier →